Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1633-1638

  Gemignani, Federica ^a,b   Landi, Stefano ^b   Moreno, Victor ^c,d   Gioia Patricola, Lydie ^a   Chabrier, Amélie ^a   Guino, Elisabet ^c   Navarro, Matilde ^c   Cambray, Maria ^c   Capellà, Gabriel ^c   Canzian, Federico ^a   Marti Ragué, Joan ^e   De Oca, Javier ^e   Osorio, Alfonso ^e   Del Rio, Carlos ^e   Biondo, Sebastiano ^e   Badosa, Josep M ^e   Vilardell, Felip ^e   Lloveras, Belen ^e   Novell, Valeri ^e   Pareja, Laura ^e   Pontes, Caridad ^e   Peinado, Miguel A ^e   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF PISA   (Italy)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e IARC ^*

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; EXPOSURE; FEMALE; GASTROINTESTINAL TRACT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2;

EID: 22244478946     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0057     Document Type: Article

References (36)

1. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301.
2. de Jong MM, Nolte IM, te Meerman GJ, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002;11:1332-52.
3. Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 2003; 89:333-7.
4. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, TNF, NFKB1, and PPARG with colorectal cancer. Cancer Res 2003;63:3560-6.
5. Yamada Y, Hamajima N, Kato T, et al. Association of a polymorphism of the phospholipase D(2) gene with the prevalence of colorectal cancer. J Mol Med 2003;81:126-31.
6. Glavin GB, Szabo S. Dopamine in gastrointestinal disease. Dig Dis Sci 1990; 35:1153-61.
7. Shibata MA, Hirose M, Yamada M, Tatematsu M, Uwagawa S, Ito N. Epithelial cell proliferation in rat forestomach and glandular stomach mucosa induced by catechols and analogous dihydroxybenzenes. Carcinogenesis 1990;11:997-1000.
8. Basu S, Dasgupta PS. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 1999; 44:916-21.
9. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003;12:205-16.
10. Li T, Arranz M, Aitchison KJ, et al. Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophr Res 1998;32:87-92.
11. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003;28:73-82.
12. Noble EP. The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 2000;1:309-33.
13. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001;105:271-4.
14. David SP, Niaura R, Papandonatos GD, et al. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 2003;5: 935-42.
15. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;6:479-84.
16. Kurg A, Tõnisson N, Georgiou I, Shumaker J, Tollett J, Metspalu A. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. Genet Test 2000;4:1-7.
17. Gemignani F, Perra C, Landi S, et al. Reliable detection of β-thalassemia and G6PD mutations by a DNA microarray. Clin Chem 2002;48:2051-4.
18. Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 2003;35:816-27.
19. Gemignani F, Landi S, Vivant F, Zienolddiny S, Brennan P, Canzian F. A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. Pharmacogenetics 2002;12:459-63.
20. Metspalu A, Shumaker JM. DNA resequencing, mutation detection and gene expression analysis by oligonucleotide microchips. Biomethods 1999;10: 371-97.
21. Guo Z, Guilfoyle RA, Thiel AJ, Wang R, Smith LM. Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports. Nucleic Acids Res 1994;22:5456-65.
22. EPIC Group of Spain. European prospective investigation into cancer and nutrition. Relative validity and reproducibility of a diet history questionnaire in Spain. I. Foods. Int J Epidemiol 1997;26 Suppl 1:591-9.
23. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73: 1162-9.
24. Finckh U, Giraldo-Velasquez M, Pelz J, et al. Dopamine D2 receptor gene (DRD2) haplotypes in Caucasians. Gene 1996;179:251-5.
25. Gelernter J, Kranzler H, Cubells JF, Ichinose H, Nagatsu T. DRD2 allele frequencies and linkage disequilibria, including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese subjects. Genomics 1998;51:21-6.
26. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577-82.
27. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998;3:256-60.
28. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 2003;116B:103-25.
29. Noble EP. The DRD2 gene, smoking, and lung cancer. J Natl Cancer Inst 1998;90:343-5.
30. Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997; 82:3864-71.
31. MacNaughton W, Wallace JL. A role for dopamine as an endogenous protective factor in the rat stomach. Gastroenterology 1989;96: 972-80.
32. Wegner IC, Dawirs RR, Grond C, Teuchert-Noodt G. Dopamine and the regulation of cell proliferation in gerbil (Meriones unguiculatus) pyloric mucosa, Life Sci 1997;60:2005-11.
33. Hayes G, Biden TJ, Selbie LA, Shine J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol 1992;6:920-6.
34. Tagliaferri P, Katsaros D, Clair T, et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site selective cAMP analogues. Cancer Res 1988;48:1642-50.
35. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 2003;206:49-62.
36. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.